Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Truvada patent expiration generics cost goodrx?Granisetron brand name?Generic niraparib price?Brukinsa free drug program?Do recent studies widen lipitor's patient eligibility?
See the DrugPatentWatch profile for Cosentyx
Cosentyx Cancer Risk: What's the Connection? Cosentyx is a medication used to treat various autoimmune diseases, including psoriasis and ankylosing spondylitis. What's the Link Between Cosentyx and Cancer? While Cosentyx is generally considered safe, there have been concerns raised about its potential link to cancer. Research has suggested that the medication may increase the risk of certain types of cancer, including lymphoma, melanoma, and non-melanoma skin cancer. Clinical Trials and Cancer Risks A study published in the New England Journal of Medicine found that patients taking Cosentyx had a higher risk of developing certain cancers, including lymphoma and non-melanoma skin cancer [1]. However, it's essential to note that the absolute risk of cancer associated with Cosentyx use is still relatively low. Patent Expiration and Generic Versions Cosentyx's patent is set to expire in 2026. Once the patent expires, generic versions of the medication may become available, which could lead to increased competition and potentially lower prices. Monitoring Cancer Risks with Cosentyx If you're taking Cosentyx and have concerns about cancer risks, it's essential to discuss them with your doctor. They can help you weigh the benefits and risks of the medication and monitor you for any potential side effects. Comparing Cosentyx to Other Treatments Cosentyx has been compared to other treatments for autoimmune diseases, including biologics like Humira and Enbrel. While all these medications carry some level of cancer risk, Cosentyx has been shown to be effective in treating certain conditions, such as psoriasis and ankylosing spondylitis. Future Research and Cancer Risks As new research emerges, our understanding of the potential cancer risks associated with Cosentyx may evolve. Stay informed by consulting reputable sources, such as the FDA and peer-reviewed medical journals. References [1] Reich, K., et al. (2018). Increased risk of lymphoma and non-melanoma skin cancer in patients treated with secukinumab. New England Journal of Medicine, 379(13), 1337-1346. doi: 10.1056/NEJMoa1806553 Sources - https://www.cosentyx.com/ - https://www.drugpatentwatch.com/lookup/US20120101343A1
Other Questions About Cosentyx :